Price T Rowe Associates Inc. MD Raises Stock Position in Boston Scientific Co. (NYSE:BSX)

Price T Rowe Associates Inc. MD boosted its position in shares of Boston Scientific Co. (NYSE:BSX – Get Rating) by 0.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,850,313 shares of the medical equipment provider’s stock after purchasing an additional 7,738 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.13% of Boston Scientific worth $71,663,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. CoreCap Advisors LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $27,000. Acadian Asset Management LLC purchased a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $35,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Boston Scientific by 68.4% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 1,000 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 406 shares during the period. Adirondack Trust Co. raised its stake in shares of Boston Scientific by 126.0% in the 3rd quarter. Adirondack Trust Co. now owns 1,130 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 630 shares during the period. Finally, Washington Trust Advisors Inc. grew its holdings in shares of Boston Scientific by 192.5% in the third quarter. Washington Trust Advisors Inc. now owns 1,284 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 845 shares in the last quarter. 90.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Wendy Carruthers sold 7,500 shares of the company’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $46.62, for a total value of $349,650.00. Following the completion of the sale, the executive vice president now owns 87,413 shares in the company, valued at approximately $4,075,194.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, EVP Arthur C. Butcher sold 27,000 shares of the company’s stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $48.74, for a total value of $1,315,980.00. Following the completion of the sale, the executive vice president now owns 23,392 shares in the company, valued at approximately $1,140,126.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Wendy Carruthers sold 7,500 shares of the company’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $46.62, for a total transaction of $349,650.00. Following the completion of the sale, the executive vice president now owns 87,413 shares of the company’s stock, valued at approximately $4,075,194.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 122,682 shares of company stock worth $5,782,324. Corporate insiders own 0.66% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their price objective on shares of Boston Scientific from $48.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, February 2nd. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Thursday, March 2nd. Stifel Nicolaus lifted their price objective on shares of Boston Scientific from $50.00 to $52.00 in a report on Wednesday, February 1st. Argus lifted their price objective on shares of Boston Scientific from $50.00 to $55.00 in a report on Friday, February 17th. Finally, Raymond James lifted their price objective on shares of Boston Scientific from $54.00 to $56.00 and gave the company a “strong-buy” rating in a report on Thursday, February 2nd. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and a consensus price target of $51.50.

Boston Scientific Trading Up 2.4 %

Shares of Boston Scientific stock opened at $47.60 on Tuesday. The company has a fifty day simple moving average of $46.70 and a 200-day simple moving average of $44.05. Boston Scientific Co. has a 12-month low of $34.98 and a 12-month high of $48.87. The company has a current ratio of 1.51, a quick ratio of 1.02 and a debt-to-equity ratio of 0.51. The stock has a market cap of $68.30 billion, a price-to-earnings ratio of 105.78, a PEG ratio of 2.19 and a beta of 0.79.

Boston Scientific (NYSE:BSX – Get Rating) last issued its earnings results on Wednesday, February 1st. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.02). Boston Scientific had a net margin of 5.50% and a return on equity of 14.29%. The company had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.24 billion. During the same quarter in the previous year, the company posted $0.45 EPS. The company’s quarterly revenue was up 3.7% on a year-over-year basis. On average, equities analysts forecast that Boston Scientific Co. will post 1.9 EPS for the current fiscal year.

About Boston Scientific

(Get Rating)

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Urology and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions.